Comparative Pharmacology
Head-to-head clinical analysis: THEOCLEAR 80 versus THEOCLEAR L A 260.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOCLEAR 80 versus THEOCLEAR L A 260.
THEOCLEAR-80 vs THEOCLEAR L.A.-260
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits phosphodiesterase, increasing cAMP levels, leading to bronchodilation and reduced airway inflammation.
Theophylline causes bronchodilation by inhibiting phosphodiesterase, increasing cAMP levels, and antagonizing adenosine receptors.
Oral: 400-800 mg every 6-8 hours; extended-release formulation given every 12 hours. Target serum concentration 10-20 mcg/mL.
Theophylline (THEOCLEAR L.A.-260) 260 mg orally every 12 hours. Adjust dose based on serum theophylline concentrations to achieve 5-15 mcg/mL.
None Documented
None Documented
3–8 hours in adults (mean ~5 h); prolonged in heart failure, liver disease, and COPD; decreased in smokers (4–5 h) and children.
Terminal elimination half-life is approximately 6-12 hours in adults (range 3-12 hours, prolonged in congestive heart failure, liver disease, and with certain drugs). In neonates, half-life is prolonged (24-36 hours).
Renal: approximately 10% unchanged; hepatic metabolism accounts for ~90% of elimination; metabolites excreted in urine.
Renal elimination of unchanged drug (10%) and hepatic metabolism (90%). Metabolism is primarily via CYP1A2 and CYP3A4, with metabolites excreted in urine (about 80% of the dose) and feces (about 20%).
Category C
Category C
Bronchodilator
Bronchodilator